Assessing advantages of sequential boron neutron capture therapy (BNCT) in an oral cancer model with normalized blood vessels

Background. We previously demonstrated the therapeutic success of sequential boron neutron capture therapy (SeqBNCT)
in the hamster cheek pouch oral cancer model. It consists of BPA-BNCT followed by GB-10-BNCT 24 or 48
hours later. Additionally, we proved that tumor blood vessel normalization with thalidomide prior to BPA-BNCT
improves tumor control. The aim of the present study was to evaluate the therapeutic efficacy and explore potential
boron microdistribution changes in Seq-BNCT preceded by tumor blood vessel normalization.
Material and Methods. Tumor bearing animals were treated with thalidomide for tumor blood vessel normalization,
followed by Seq-BNCT (ThSeq-BNCT) or Seq-Beam Only (ThSeq-BO) in the window of normalization. Boron
microdistribution was assessed by neutron autoradiography.
Results. ThSeq-BNCT induced overall tumor response of 100%, with 87 (4)% complete tumor response. No cases
of severe mucositis in dose-limiting precancerous tissue were observed. Differences in boron homogeneity between
tumors pre-treated and not pre-treated with thalidomide were observed.
Conclusion. ThSeq-BNCT achieved, for the first time, response in all treated tumors. Increased homogeneity in
tumor boron microdistribution is associated to an improvement in tumor control.